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We have monitored the ligand binding of the bovine hippocampal 5-HT1A receptor following treatment with the sterol-binding
antifungal antibiotic nystatin. Nystatin considerably inhibits the specific binding of the antagonist to 5-HT1A receptors in a con-
centration-dependent manner. However, the specific agonist binding does not show significant changes. Fluorescence polarization
measurements of membrane probes incorporated at different locations in the membrane revealed a substantial decrease in the
membrane order in the interior of the bilayer. Experiments with cholesterol-depleted membranes indicate that the action of nystatin
is mediated through membrane cholesterol. These results represent the first report on the effect of a cholesterol-perturbing agent on
the ligand-binding activity of this important neurotransmitter receptor.
 2004 Elsevier Inc. All rights reserved.
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trinsically fluorescent [1], biogenic amine which acts as a
neurotransmitter and is found in a wide variety of sites in
the central and peripheral nervous system [2]. Seroto-
nergic signaling appears to play a key role in the genera-
tion and modulation of various cognitive and behavioral
functions such as sleep, mood, pain, addiction, locomo-
tion, sexual activity, depression, anxiety, alcohol abuse,
aggression, and learning [3–5]. Disruptions in serotoner-
gic systems have been implicated in the etiology of mental
disorders such as schizophrenia, migraine, depression,
suicidal behavior, infantile autism, eating disorders, and
obsessive compulsive disorder [4,6,7].qAbbreviations: BCA, bicinchoninic acid; 5-HT, 5-hydroxytrypta-
mine; DMPC, dimyristoyl-sn-glycero-3-phosphocholine; DPH, 1,
6-diphenyl-1,3,5-hexatriene; 8-OH-DPAT, 8-hydroxy-2-(di-N -propyl-
amino)tetralin; MbCD, methyl-b-cyclodextrin; p-MPPF, 4-(20-meth-
oxy)-phenyl-1-[20-(N -200-pyridinyl)-p-fluorobenzamido]ethyl-piperazine;
p-MPPI, 4-(20-methoxy)-phenyl-1-[20-(N -200-pyridinyl)-p-iodobenzam-
ido]ethyl-piperazine; PMSF, phenylmethylsulfonyl fluoride; TMA-
DPH, 1-[4-(trimethylammonio)phenyl]-6-phenyl-1,3,5-hexatriene; Tris,
tris-(hydroxymethyl)aminomethane.
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doi:10.1016/j.bbrc.2004.06.004Serotonin exerts its diverse actions by binding to
distinct cell surface receptors which have been classified
into many groups [8]. Serotonin receptors are members
of a superfamily of seven transmembrane domain re-
ceptors [9] that couple to GTP-binding regulatory pro-
teins (G-proteins) [10]. Among the 14 subtypes of
serotonin receptors, the G-protein-coupled 5-HT1A re-
ceptor is the best characterized for a variety of reasons
[11]. The hippocampal 5-HT1A receptor is negatively
coupled to the adenylate cyclase through Gi-proteins
[12]. We have earlier solubilized and partially purified
the 5-HT1A receptor from bovine hippocampus in a
functionally active form [13,14]. In addition, we have
shown modulation of ligand binding by metal ions
[15,16], agents that perturb G-proteins [17,18], alcohols
[19,20], local anesthetics [21], and covalent modifications
of the disulfide and sulfhydryl groups [11].
Lipid–protein interactions play a crucial role in
maintaining the structure and function of integral
membrane proteins and receptors [22]. We have recently
shown the requirement of membrane cholesterol in
modulating ligand-binding activity of the 5-HT1A re-
ceptor from the bovine hippocampus [23]. This was
achieved by the use of methyl-b-cyclodextrin (MbCD)
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Treatment of bovine hippocampal membranes with
MbCD therefore resulted in specific removal of mem-
brane cholesterol without any change in phospholipid
content. Removal of cholesterol from bovine hippo-
campal membranes in this manner resulted in a reduc-
tion in ligand binding to the 5-HT1A receptor [23]. If
cholesterol is necessary for ligand binding of the 5-HT1A
receptor, modulating cholesterol availability by other
means could affect ligand binding. In this report, we
have tested this proposal by treating the membranes
with the sterol-binding antifungal polyene antibiotic
nystatin [24–26]. Nystatin specifically interacts with
cholesterol to sequester it in the membrane thereby ef-
fectively reducing the ability of cholesterol to interact
with and exert its effects on other membrane compo-
nents such as receptors. In this work, we monitored li-
gand binding of the 5-HT1A receptor in hippocampal
membranes treated with nystatin. Our results show that
while ligand binding to this receptor is perturbed by
nystatin treatment, there are interesting differences from
what was observed with cholesterol depletion by MbCD
treatment.VV VHMaterials and methods
Materials. BCA, DMPC, DPH, EDTA, EGTA, MbCD, MgCl2,
MnCl2; Na2HPO4, nystatin, p-MPPI, PMSF, TMA-DPH, Tris, iodo-
acetamide, polyethylenimine, serotonin, sodium azide, and sucrose
were obtained from Sigma Chemical (St. Louis, MO, USA). [3H]8-OH-
DPAT (specific activity 135.0Ci/mmol) and [3H]p-MPPF (specific
activity 70.5Ci/mmol) were purchased from DuPont New England
Nuclear (Boston, MA, USA). BCA reagent kit for protein estimation
was obtained from Pierce (Rockford, IL, USA). All other chemicals
used were of the highest available quality. GF/B glass microfiber filters
were from Whatman International (Kent, UK). Fresh bovine brains
were obtained from a local slaughterhouse within 10min of death and
the hippocampal region was carefully dissected out. The hippocampi
were immediately flash-frozen in liquid nitrogen and stored at )70 C
until further use.
Preparation of native hippocampal membranes. Native hippocampal
membranes were prepared as described earlier [15]. Bovine hippo-
campal tissue (100 g) was homogenized as 10% (w/v) in a polytron
homogenizer in buffer A (2.5mM Tris, 0.32M sucrose, 5mM EDTA,
5mM EGTA, 0.02% sodium azide, 0.24mM PMSF, and 10mM io-
doacetamide, pH 7.4). The homogenate was centrifuged at 900g for
10min at 4 C. The supernatant was filtered through four layers of
cheesecloth and the pellet was discarded. The supernatant was further
centrifuged at 50,000g for 20min at 4 C. The resulting pellet was
suspended in 10 vol of buffer B (50mM Tris, 1mM EDTA, 0.24mM
PMSF, and 10mM iodoacetamide, pH 7.4) using a hand-held Dounce
homogenizer and centrifuged at 50,000g for 20min at 4 C. This pro-
cedure was repeated until the supernatant was clear. The final pellet
(native membranes) was resuspended in a minimum volume of buffer C
(50mM Tris, pH 7.4), homogenized using a hand-held Dounce ho-
mogenizer, flash-frozen in liquid nitrogen, and stored at )70 C until
further use. Protein concentration was determined using the BCA
reagent with bovine serum albumin as a standard [27].
Radioligand-binding assays. Receptor-binding assays were carried
out as described earlier [21] in the presence of increasing concentra-
tions of nystatin. Stock solutions of nystatin (4mM) were prepared inwater and briefly sonicated in a bath sonicator (Laboratory Supplies,
Hicksville, NY, USA) before use. Tubes in duplicate containing 0.5mg
total protein in a volume of 1ml buffer D (50mM Tris, 1mM EDTA,
10mM MgCl2, and 5mM MnCl2, pH 7.4) for agonist binding or in
1ml buffer E (50mM Tris, 1mM EDTA, pH 7.4) for antagonist-
binding assays were used. Tubes were incubated with the radiolabeled
agonist [3H]8-OH-DPAT (final concentration in assay tube being
0.29 nM) or antagonist [3H]p-MPPF (final concentration in assay tube
being 0.5 nM) for 1 h at room temperature (23 C) in presence of in-
creasing concentrations of nystatin. Non-specific binding was deter-
mined by performing the assay either in the presence of 10 lM
serotonin (for agonist-binding assays) or in the presence of 10 lM
p-MPPI (for antagonist-binding assays). The binding reaction was
terminated by rapid filtration under vacuum in a Millipore multiport
filtration apparatus through Whatman GF/B 2.5 cm diameter glass
microfiber filters (1.0lm pore size) which were presoaked in 0.15% (w/
v) polyethylenimine for 1 h [28]. The filters were then washed three
times with 3ml cold water (4 C), dried, and the retained radioactivity
was measured in a Packard Tri-Carb 1500 liquid scintillation counter
using 5ml scintillation fluid.
Cholesterol depletion of native membranes. Native hippocampal
membranes were depleted of cholesterol using MbCD as described
previously [23,34]. Briefly, membranes resuspended at a protein con-
centration of 2mg/ml were treated with 40mM MbCD in buffer C at
room temperature (23 C) with constant shaking for 1 h. Membranes
were then spun down at 50,000g for 5min, washed with buffer C, and
resuspended in the same buffer. Cholesterol was estimated using the
Amplex Red cholesterol assay kit [29]. Concentration of lipid phos-
phate was determined subsequent to total digestion by perchloric acid
[30] using Na2HPO4 as a standard. DMPC was used as an internal
standard to assess lipid digestion.
Fluorescence polarization measurements. Fluorescence polarization
experiments were carried out with membranes containing 50 nmol of
total phospholipids suspended in 1.5ml buffer C as described earlier
[23,34] in presence of increasing concentrations of nystatin. Stock
solutions of the fluorescent probes (DPH and TMA-DPH) were
prepared in methanol. The amount of probe added was such that the
final probe concentration was 1mol% with respect to the total
phospholipid content. This ensures optimal fluorescence intensity
with negligible membrane perturbation. Membranes were vortexed
for 1min after addition of the probe and kept in the dark for 1 h
before measurements. Background samples were prepared the same
way except that the probe was omitted. The final probe concentra-
tion was 0.33lM in all cases and the methanol content was low
(0.03%, v/v). Control experiments showed that at this concentration
of methanol, the ligand-binding properties of the receptor are not
altered.
Steady state fluorescence was measured in a Hitachi F-4010 spec-
trofluorometer using 1 cm path length quartz cuvettes at room tem-
perature (23 C). Excitation and emission wavelengths were set at 358
and 430 nm. Excitation and emission slits with nominal bandpasses of
1.5 and 20 nm were used. The excitation slit was kept low to avoid any
photoisomerization of DPH. In addition, fluorescence was measured
with a 30 s interval between successive openings of the excitation
shutter (when the sample was in the dark in the fluorimeter) to reverse
any photoisomerization of DPH and TMA-DPH [31]. The optical
density of the samples measured at 358 nm was 0.15 0.01 which in-
creased in presence of nystatin. To avoid scattering artifacts in these
experiments, fluorescence polarization was measured after membrane
samples were diluted with buffer C [32]. The fluorescence polarization
values reported in Fig. 2 are of the most diluted samples (three times
with buffer C). Fluorescence polarization measurements were per-
formed using a Hitachi polarization accessory. Polarization values
were calculated from the equation [33]:
P ¼ IVV  GIVH
I þ GI ; ð1Þ
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appropriate background subtraction) with the excitation polarizer
vertically oriented and the emission polarizer vertically and horizon-
tally oriented, respectively. G is the instrumental correction factor and
is the ratio of the efficiencies of the detection system for vertically and
horizontally polarized light and is equal to IHV/IHH. All experiments
were done with multiple sets of samples and average values of fluo-
rescence polarization are shown in Fig. 2.Results
We monitored the ability of nystatin to affect the
ligand binding of 5-HT1A receptors in native hippo-
campal membranes. As mentioned earlier, nystatin
specifically interacts with cholesterol [26] to sequester it
in the membrane thereby effectively reducing the ability
of cholesterol to interact with other membrane constit-
uents such as receptors. Fig. 1 shows the effect of in-
creasing concentrations of nystatin on ligand binding to
bovine hippocampal 5-HT1A receptors. It is apparent
from the figure that nystatin inhibits the specific binding
of the radiolabeled antagonist [3H]p-MPPF to 5-HT1A
receptors to a considerable extent in a concentration-
dependent manner. Thus, the specific antagonist binding
to 5-HT1A receptors reduces by 66% when nystatin is
used at an 8-fold molar excess over membrane choles-
terol. In contrast to this, the specific radiolabeled ago-
nist [3H]8-OH-DPAT binding to 5-HT1A receptors does
not exhibit significant alterations in presence of similarFig. 1. Effect of increasing concentrations of nystatin on the specific
binding of the agonist [3H]8-OH-DPAT (s) and antagonist [3H]p-
MPPF (d) to the 5-HT1A receptor in bovine hippocampal membranes.
Nystatin concentrations are expressed as the ratio of nystatin to
membrane cholesterol (mol/mol) and were based on the cholesterol
content of bovine hippocampal membranes which was estimated to be
433 nmol/mg protein, similar to the previously reported value [34].
Values are expressed as a percentage of the specific binding obtained in
the absence of nystatin. The data shown are means SE of duplicate
points from four independent experiments. See Materials and methods
for other details.concentrations of nystatin. The difference in the effects
of nystatin on the agonist and antagonist binding to 5-
HT1A receptors points toward a specific mode of action
of nystatin on the receptor.
The agonist 8-OH-DPAT and antagonist p-MPPF
have earlier been shown to specifically bind to bovine
hippocampal 5-HT1A receptors with high affinity [15–
17,23]. The greater sensitivity of the antagonist [3H]p-
MPPF binding of 5-HT1A receptors to the sterol-binding
agent nystatin could indicate a stringent requirement of
the native-like distribution of cholesterol in membranes
to support the antagonist-binding function of these re-
ceptors. We have recently shown the requirement of
membrane cholesterol for the agonist [3H]8-OH-DPAT
[23] and the antagonist [3H]p-MPPF (T.J. Pucadyil and
A. Chattopadhyay, unpublished observations) binding
of 5-HT1A receptors. Thus, physical depletion of cho-
lesterol from membranes using MbCD reduces agonist
and antagonist binding of 5-HT1A receptors to similar
extents. In the backdrop of these results, it is interesting
that the treatment of hippocampal membranes with the
sterol-binding agent nystatin affects the antagonist
[3H]p-MPPF but not the agonist [3H]8-OH-DPAT
binding to 5-HT1A receptors. From the present results, it
appears that the mere presence of cholesterol (even in
complexed form) could be sufficient to support the ag-
onist binding to 5-HT1A receptors whereas the antago-
nist binding requires the presence of native-like
distribution of cholesterol in the membrane. These re-
sults thus further refine the role of membrane cholesterol
in modulating ligand binding to 5-HT1A receptors.
Nystatin is a membrane-active polyene antibiotic that
effectively partitions into membranes [35]. It has been
proposed that nystatin forms a 1:1 (mol/mol) complex
with membrane cholesterol and forms channels in the
membrane [36]. A large portion of any given trans-
membrane protein, the 5-HT1A receptor in this case,
remains in contact with the membrane lipid environ-
ment. This raises the obvious possibility that the overall
membrane order and dynamics could be an important
modulator of receptor structure and function [22,37]. In
order to examine any change in membrane order in-
duced by the partitioning of nystatin, we monitored the
steady state fluorescence polarization of two membrane
probes, DPH and TMA-DPH. DPH and its derivatives
represent popular membrane probes for monitoring
organization and dynamics in membranes [38]. Fluo-
rescence polarization is correlated to the rotational dif-
fusion [33] of membrane embedded probes which is
sensitive to the packing of fatty acyl chains and cho-
lesterol. Since the membrane is considered to be a two-
dimensional anisotropic fluid, any possible change in
membrane order may not be uniform or restricted to a
unique location in the membrane. It is therefore
important to monitor the change in membrane order
at multiple regions in the membrane to obtain a
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brane (lipid) dynamics. DPH and TMA-DPH differ in
their orientation and location in the membrane. While
DPH is known to partition into the hydrophobic core of
the membrane [39], the amphipathic TMA-DPH is ori-
ented in the membrane bilayer with its positive charge
localized at the lipid–water interface [40].
The change in fluorescence polarization of DPH and
TMA-DPH incorporated in hippocampal membranes
treated with increasing concentrations of nystatin is
shown in Fig. 2. The fluorescence polarization of DPH
and TMA-DPH in hippocampal membranes (without
any nystatin) is found to be 0.332 and 0.359, respec-
tively. The higher polarization of TMA-DPH compared
to DPH is indicative of the shallower location and
therefore of greater restriction in the rotational mobility
of TMA-DPH in the membrane, as has been observed
earlier for anthroyloxy-labeled fluorescent membrane
probes [41]. The fluorescence polarization of DPH
shows a decrease with increasing concentrations of
nystatin, with a 9% decrease when nystatin is used at a
6-fold molar excess over membrane cholesterol. The
corresponding change in fluorescence polarization of
TMA-DPH is much smaller. Thus, the percentage
change in fluorescence polarization is higher for DPH
compared to TMA-DPH in presence of nystatin indi-
cating a greater membrane disordering effect in the hy-
drophobic interior of the membrane than in the
shallower region of the membrane. It is worth men-
tioning here that the presence of nystatin contributed
significantly to the optical density of membrane samplesFig. 2. Effect of increasing concentrations of nystatin on fluorescence
polarization of membrane probes DPH (s) and TMA-DPH (d).
Fluorescence polarization experiments were carried out with mem-
branes containing 50 nmol phospholipid at a probe to phospholipid
ratio of 1:100 (mol/mol) at room temperature (23 C) that were diluted
three times to avoid scattering artifacts. Nystatin concentrations are
expressed as the ratio of nystatin to membrane cholesterol (mol/mol).
The data shown represent means SE of at least six independent ex-
periments. See Materials and methods for other details.used for these studies. To avoid any scattering artifacts
in the determination of polarization values, fluorescence
polarization was measured after membrane samples
were sufficiently diluted, as described earlier [32]. The
fluorescence polarization values reported in Fig. 2 are of
the most diluted samples (three times with buffer C)
which ensured accuracy in the determination of polari-
zation values. Thus, the presence of nystatin substan-
tially decreased the membrane order in the interior of
the bilayer and is accompanied by a greater reduction in
the antagonist binding compared to the agonist-binding
activity of the 5-HT1A receptor.
The nature and specificity of nystatin and sterol
(cholesterol in mammalian membranes) interaction has
been analyzed quite extensively [26]. Studies on ion
permeability induced by the presence of nystatin–sterol
pore complexes in model membranes suggest that the
action of nystatin is considerably enhanced in the pres-
ence of membrane sterols. This is evident from the 10-
fold higher amounts of nystatin required to bring about
a similar increase in ion permeability in membranes
lacking sterols [26]. To further analyze the specificity of
the action of nystatin in reducing the antagonist binding
to 5-HT1A receptors, we performed similar experiments
as described in Fig. 1 with cholesterol-depleted mem-
branes. These experiments (shown in Fig. 3) indicate
that the prior depletion of 87% cholesterol (estimated
using the Amplex Red assay, see Materials andFig. 3. Effect of increasing concentrations of nystatin on the specific
binding of the agonist [3H]8-OH-DPAT (s) and antagonist [3H]p-
MPPF (d) to the 5-HT1A receptor from bovine hippocampal
membranes depleted of cholesterol using 40mM MbCD. Nystatin
concentrations are expressed as the ratio of nystatin to membrane
cholesterol (mol/mol) and were based on the cholesterol content of
MbCD-treated bovine hippocampal membranes which was estimated
to be 57 nmol/mg protein, similar to the previously reported value
[34]. Values are expressed as a percentage of the specific binding
obtained in the absence of nystatin. The values are meansSE of
duplicate points from three independent experiments. See Materials
and methods for other details.
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effect of nystatin on the specific antagonist [3H]p-MPPF
binding to 5-HT1A receptors. Thus, the specific antago-
nist binding to 5-HT1A receptors reduces by 22% when
nystatin is used at an 8-fold molar excess over mem-
brane cholesterol in cholesterol-depleted membranes
(Fig. 3), as compared to 66% reduction observed for
control membranes (Fig. 1). As observed earlier (Fig. 1),
the specific agonist [3H]8-OH-DPAT binding shows no
significant variation under these conditions. These re-
sults indicate that the action of nystatin to reduce the
antagonist binding to 5-HT1A receptors is mediated
through membrane cholesterol.Discussion
Cholesterol is an essential component of eukaryotic
membranes and plays a crucial role in membrane or-
ganization, dynamics, function, and sorting [42,43]. It is
often found distributed non-randomly in domains or
pools in biological and model membranes [44–46]. Many
of these domains are believed to be important for the
maintenance of membrane structure and function. The
membrane organization of G-protein-coupled receptors,
such as 5-HT1A receptors, in relation to these domains
assumes significance in light of their role in health and
disease [47]. Recent evidence has indicated that a
spatiotemporally organized system rather than a freely
diffusible system of receptors and G-proteins is respon-
sible for rapid and specific propagation of extracellular
stimuli to intracellular signaling molecules [48,49]. It has
been proposed that G-protein-coupled receptors are not
uniformly present on the plasma membrane but are
concentrated in specific membrane microdomains [48–
51], some of which are presumably enriched in choles-
terol [43,46]. Importantly, the integrity of some of these
domains is maintained by the presence of cholesterol
[52]. In this regard, the analysis of membrane protein
function under conditions that affect membrane cho-
lesterol content, availability, and distribution assumes
greater significance.
This report represents one of the first studies on the
effect of agents that perturb membrane cholesterol on
the ligand-binding activity of this important neuro-
transmitter receptor. These results demonstrate inter-
esting differences in the manner by which cholesterol
modulates ligand-binding activity of hippocampal 5-
HT1A receptors depending on the exact approach used
to perturb membrane cholesterol (i.e., by depletion
with agents such as MbCD or complexation with
nystatin). In addition, our results show the important
role played by cholesterol in regulation of ligand-
binding activity of the 5-HT1A receptor. More impor-
tantly, these results are relevant in the general context
of the influence of the membrane lipid environment onthe activity of G-protein-coupled transmembrane
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